fig4

From: ImmuneScore as a novel RNA-based prognostic signature superior to PD-L1 in advanced non-squamous NSCLC patients receiving chemotherapy combined with immune checkpoint inhibitor therapy

ImmuneScore as a novel RNA-based prognostic signature superior to PD-L1 in advanced non-squamous NSCLC patients receiving chemotherapy combined with immune checkpoint inhibitor therapy

Figure 4. Construction of prognostic nomogram models. (A) Prognostic nomogram model construction for PFS prediction; (B) ROC curves and corresponding AUCs for variables in predicting PFS; (C) Prognostic nomogram model construction for OS prediction; (D) ROC curves and corresponding AUCs for variables in predicting OS. NSCLC: Non-squamous cell lung cancer; ICI: immune checkpoint inhibitor; PFS: progression-free survival; OS: overall survival.

fig4

Portico

Portico